Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. / Yafasova, Adelina; Fosbøl, Emil L; Schou, Morten; Gustafsson, Finn; Rossing, Kasper; Bundgaard, Henning; Lauridsen, Marie D; Kristensen, Søren L; Torp-Pedersen, Christian; Gislason, Gunnar H; Køber, Lars; Butt, Jawad H.

In: Journal of the American College of Cardiology, Vol. 76, No. 7, 2020, p. 767-777.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Yafasova, A, Fosbøl, EL, Schou, M, Gustafsson, F, Rossing, K, Bundgaard, H, Lauridsen, MD, Kristensen, SL, Torp-Pedersen, C, Gislason, GH, Køber, L & Butt, JH 2020, 'Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis', Journal of the American College of Cardiology, vol. 76, no. 7, pp. 767-777. https://doi.org/10.1016/j.jacc.2020.06.038

APA

Yafasova, A., Fosbøl, E. L., Schou, M., Gustafsson, F., Rossing, K., Bundgaard, H., Lauridsen, M. D., Kristensen, S. L., Torp-Pedersen, C., Gislason, G. H., Køber, L., & Butt, J. H. (2020). Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. Journal of the American College of Cardiology, 76(7), 767-777. https://doi.org/10.1016/j.jacc.2020.06.038

Vancouver

Yafasova A, Fosbøl EL, Schou M, Gustafsson F, Rossing K, Bundgaard H et al. Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. Journal of the American College of Cardiology. 2020;76(7):767-777. https://doi.org/10.1016/j.jacc.2020.06.038

Author

Yafasova, Adelina ; Fosbøl, Emil L ; Schou, Morten ; Gustafsson, Finn ; Rossing, Kasper ; Bundgaard, Henning ; Lauridsen, Marie D ; Kristensen, Søren L ; Torp-Pedersen, Christian ; Gislason, Gunnar H ; Køber, Lars ; Butt, Jawad H. / Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. In: Journal of the American College of Cardiology. 2020 ; Vol. 76, No. 7. pp. 767-777.

Bibtex

@article{f84ae39334524da4bc8350b1a9ed066a,

title = "Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis",

abstract = "BACKGROUND: It is estimated that 5% of patients with sarcoidosis have clinically manifest cardiac involvement, although autopsy and imaging studies suggest a significantly higher prevalence of cardiac involvement. There is a paucity of contemporary data on the risk of adverse cardiac outcomes, particularly heart failure (HF), in patients with sarcoidosis.OBJECTIVES: The purpose of this study was to examine the long-term risk of HF and other adverse cardiac outcomes in patients with sarcoidosis compared with matched control subjects.METHODS: In this cohort study, all patients age ≥18 years with newly diagnosed sarcoidosis (1996 to 2016) were identified through Danish nationwide registries and matched 1:4 by age, sex, and comorbidities with control subjects from the background population without sarcoidosis.RESULTS: Of the 12,042 patients diagnosed with sarcoidosis, 11,834 patients were matched with 47,336 subjects from the background population (median age: 42.8 years [25th to 75th percentile: 33.1 to 55.8 years], 54.3% men). The median follow-up was 8.2 years. Absolute 10-year risks of outcomes were as follows: HF: 3.18% (95% confidence interval [CI]: 2.83% to 3.57%) for sarcoidosis patients and 1.72% (95% CI: 1.58% to 1.86%) for the background population; the composite of ICD implantation, ventricular arrhythmias, and cardiac arrest: 0.96% (95% CI: 0.77% to 1.18%) for sarcoidosis patients and 0.45% (95% CI: 0.38% to 0.53%) for the background population; the composite of pacemaker implantation, atrioventricular block, and sinoatrial dysfunction: 0.94% (95% CI: 0.75% to 1.16%) for sarcoidosis patients and 0.51% (95% CI: 0.44% to 0.59%) for the background population; atrial fibrillation or flutter: 3.44% (95% CI: 3.06% to 3.84%) for sarcoidosis patients and 2.66% (95% CI: 2.49% to 2.84%) for the background population; and all-cause mortality: 10.88% (95% CI: 10.23% to 11.55%) for sarcoidosis patients and 7.43% (95% CI: 7.15% to 7.72%) for the background population.CONCLUSIONS: Patients with sarcoidosis had a higher associated risk of HF and other adverse cardiac outcomes compared with matched control subjects.",

author = "Adelina Yafasova and Fosb{\o}l, {Emil L} and Morten Schou and Finn Gustafsson and Kasper Rossing and Henning Bundgaard and Lauridsen, {Marie D} and Kristensen, {S{\o}ren L} and Christian Torp-Pedersen and Gislason, {Gunnar H} and Lars K{\o}ber and Butt, {Jawad H}",

year = "2020",

doi = "10.1016/j.jacc.2020.06.038",

language = "English",

volume = "76",

pages = "767--777",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier",

number = "7",

}

RIS

TY - JOUR

T1 - Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis

AU - Yafasova, Adelina

AU - Fosbøl, Emil L

AU - Schou, Morten

AU - Gustafsson, Finn

AU - Rossing, Kasper

AU - Bundgaard, Henning

AU - Lauridsen, Marie D

AU - Kristensen, Søren L

AU - Torp-Pedersen, Christian

AU - Gislason, Gunnar H

AU - Køber, Lars

AU - Butt, Jawad H

PY - 2020

Y1 - 2020

N2 - BACKGROUND: It is estimated that 5% of patients with sarcoidosis have clinically manifest cardiac involvement, although autopsy and imaging studies suggest a significantly higher prevalence of cardiac involvement. There is a paucity of contemporary data on the risk of adverse cardiac outcomes, particularly heart failure (HF), in patients with sarcoidosis.OBJECTIVES: The purpose of this study was to examine the long-term risk of HF and other adverse cardiac outcomes in patients with sarcoidosis compared with matched control subjects.METHODS: In this cohort study, all patients age ≥18 years with newly diagnosed sarcoidosis (1996 to 2016) were identified through Danish nationwide registries and matched 1:4 by age, sex, and comorbidities with control subjects from the background population without sarcoidosis.RESULTS: Of the 12,042 patients diagnosed with sarcoidosis, 11,834 patients were matched with 47,336 subjects from the background population (median age: 42.8 years [25th to 75th percentile: 33.1 to 55.8 years], 54.3% men). The median follow-up was 8.2 years. Absolute 10-year risks of outcomes were as follows: HF: 3.18% (95% confidence interval [CI]: 2.83% to 3.57%) for sarcoidosis patients and 1.72% (95% CI: 1.58% to 1.86%) for the background population; the composite of ICD implantation, ventricular arrhythmias, and cardiac arrest: 0.96% (95% CI: 0.77% to 1.18%) for sarcoidosis patients and 0.45% (95% CI: 0.38% to 0.53%) for the background population; the composite of pacemaker implantation, atrioventricular block, and sinoatrial dysfunction: 0.94% (95% CI: 0.75% to 1.16%) for sarcoidosis patients and 0.51% (95% CI: 0.44% to 0.59%) for the background population; atrial fibrillation or flutter: 3.44% (95% CI: 3.06% to 3.84%) for sarcoidosis patients and 2.66% (95% CI: 2.49% to 2.84%) for the background population; and all-cause mortality: 10.88% (95% CI: 10.23% to 11.55%) for sarcoidosis patients and 7.43% (95% CI: 7.15% to 7.72%) for the background population.CONCLUSIONS: Patients with sarcoidosis had a higher associated risk of HF and other adverse cardiac outcomes compared with matched control subjects.

AB - BACKGROUND: It is estimated that 5% of patients with sarcoidosis have clinically manifest cardiac involvement, although autopsy and imaging studies suggest a significantly higher prevalence of cardiac involvement. There is a paucity of contemporary data on the risk of adverse cardiac outcomes, particularly heart failure (HF), in patients with sarcoidosis.OBJECTIVES: The purpose of this study was to examine the long-term risk of HF and other adverse cardiac outcomes in patients with sarcoidosis compared with matched control subjects.METHODS: In this cohort study, all patients age ≥18 years with newly diagnosed sarcoidosis (1996 to 2016) were identified through Danish nationwide registries and matched 1:4 by age, sex, and comorbidities with control subjects from the background population without sarcoidosis.RESULTS: Of the 12,042 patients diagnosed with sarcoidosis, 11,834 patients were matched with 47,336 subjects from the background population (median age: 42.8 years [25th to 75th percentile: 33.1 to 55.8 years], 54.3% men). The median follow-up was 8.2 years. Absolute 10-year risks of outcomes were as follows: HF: 3.18% (95% confidence interval [CI]: 2.83% to 3.57%) for sarcoidosis patients and 1.72% (95% CI: 1.58% to 1.86%) for the background population; the composite of ICD implantation, ventricular arrhythmias, and cardiac arrest: 0.96% (95% CI: 0.77% to 1.18%) for sarcoidosis patients and 0.45% (95% CI: 0.38% to 0.53%) for the background population; the composite of pacemaker implantation, atrioventricular block, and sinoatrial dysfunction: 0.94% (95% CI: 0.75% to 1.16%) for sarcoidosis patients and 0.51% (95% CI: 0.44% to 0.59%) for the background population; atrial fibrillation or flutter: 3.44% (95% CI: 3.06% to 3.84%) for sarcoidosis patients and 2.66% (95% CI: 2.49% to 2.84%) for the background population; and all-cause mortality: 10.88% (95% CI: 10.23% to 11.55%) for sarcoidosis patients and 7.43% (95% CI: 7.15% to 7.72%) for the background population.CONCLUSIONS: Patients with sarcoidosis had a higher associated risk of HF and other adverse cardiac outcomes compared with matched control subjects.

U2 - 10.1016/j.jacc.2020.06.038

DO - 10.1016/j.jacc.2020.06.038

M3 - Journal article

C2 - 32792073

VL - 76

SP - 767

EP - 777

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 7

ER -

ID: 250542755